Lee et al. demonstrated that in estrogen receptor (ER)-negative basal-like breast cancer cells, EZH2 physically interacts with nuclear factor-kappaB (NF-κB) components RelA/RelB as a ternary complex to activate a subset of NF-κB target genes independently of its HMTase activity [21] (Fig.2C, top). Here, EZH2 is linked to breast carcinoma.